Improvements were also found during the third day of treatment, the 28th day and the 45th, according to results published July 26 in the American Journal of Psychiatry.
The trial included 196 patients experiencing postpartum depression, giving them either a placebo or the zuranolone for treatment over the course of 45 days.
Overall, researchers wrote that “zuranolone demonstrated significant improvements in depressive symptoms and was generally well tolerated, supporting the potential of zuranolone as a novel, rapid-acting oral treatment for PPD.”
The only noted adverse effects from the drug included somnolence, dizziness and sedation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
